Connect Biopharma Holdings (CNTB) Current Deferred Revenue (2023 - 2025)

Connect Biopharma Holdings (CNTB) has reported Current Deferred Revenue for 3 consecutive years, with $167000.0 the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue rose 1.83% year-over-year to $167000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $167000.0 (up 1.83% YoY) and the FY2025 annual result came in at $167000.0, up 1.83% from the prior year.
• Current Deferred Revenue advanced to $167000.0 in Q4 2025 per CNTB's latest filing, from $165000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for CNTB reached as high as $13.3 million in Q4 2023 and fell as low as $164000.0 in Q4 2024.
• A 3-year average of $3.0 million and a median of $165000.0 in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue sank 98.77% — and 2025, when it advanced 1.83%.
• Year by year, Current Deferred Revenue stood at $13.3 million in 2023, then plunged by 98.77% to $164000.0 in 2024, then grew by 1.83% to $167000.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $167000.0, $165000.0, and $164000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.